Liver cancer: Approaching a personalized care.

[1]  Claude B. Sirlin,et al.  LI‐RADS (Liver Imaging Reporting and Data System): Summary, discussion, and consensus of the LI‐RADS Management Working Group and future directions , 2015, Hepatology.

[2]  J. Bruix,et al.  SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  J. Bruix,et al.  Portal hypertension and the outcome of surgery for hepatocellular carcinoma in compensated cirrhosis: A systematic review and meta‐analysis , 2015, Hepatology.

[4]  Frank van Hees,et al.  Smarter screening for cancer: possibilities and challenges of personalization. , 2014, JAMA.

[5]  Hiromi Nakamura,et al.  Trans-ancestry mutational landscape of hepatocellular carcinoma genomes , 2014, Nature Genetics.

[6]  P. Nahon,et al.  Genetic predisposition to hepatocellular carcinoma in alcoholic cirrhosis: the NCAN-PNPLA3-lipid connection? , 2014, Journal of hepatology.

[7]  V. Mazzaferro,et al.  Early Hepatocellular Carcinoma on the Procrustean Bed of Ablation, Resection, and Transplantation , 2014, Seminars in Liver Disease.

[8]  J. Bruix,et al.  Systemic Therapy for Hepatocellular Carcinoma: The Issue of Treatment Stage Migration and Registration of Progression Using the BCLC-Refined RECIST , 2014, Seminars in Liver Disease.

[9]  M. Sherman,et al.  Hepatocellular Carcinoma Screening and Diagnosis , 2014, Seminars in Liver Disease.

[10]  R. Poon,et al.  Recent Advances in the Prevention of Hepatocellular Carcinoma Recurrence , 2014, Seminars in Liver Disease.

[11]  V. Mazzaferro,et al.  Toward a Better Liver Graft Allocation That Accounts for Candidates With and Without Hepatocellular Carcinoma , 2014, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[12]  Nobhojit Roy,et al.  Global, regional, and national levels and causes of maternal mortality during 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013 , 2014, The Lancet.

[13]  M. Kudo,et al.  LBA16RAMUCIRUMAB (RAM) AS SECOND-LINE TREATMENT IN PATIENTS (PTS) WITH ADVANCED HEPATOCELLULAR CARCINOMA (HCC) FOLLOWING FIRST-LINE THERAPY WITH SORAFENIB: RESULTS FROM THE RANDOMIZED PHASE III REACH STUDY , 2014 .

[14]  S. Roman,et al.  Combined hepatocellular‐cholangiocarcinoma: A population‐level analysis of an uncommon primary liver tumor , 2014, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[15]  J. Bruix,et al.  Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib. , 2014, Journal of hepatology.

[16]  K. Ross,et al.  Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer , 2014, Nature.

[17]  M. Kudo,et al.  Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial. , 2014, JAMA.

[18]  T. Pawlik,et al.  Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. , 2014, Journal of hepatology.

[19]  J. Bruix,et al.  Intrahepatic Cholangiocarcinoma or Mixed Hepatocellular-Cholangiocarcinoma in Patients Undergoing Liver Transplantation: A Spanish Matched Cohort Multicenter Study , 2014, Annals of surgery.

[20]  Y. Totoki,et al.  Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma , 2014, Hepatology.

[21]  P. Schirmacher,et al.  Human and mouse VEGFA-amplified hepatocellular carcinomas are highly sensitive to sorafenib treatment. , 2014, Cancer discovery.

[22]  B. Abdullah,et al.  Phase 3, randomized, double-blind, dummy-controlled, trial of radiofrequency ablation (RFA) + lyso-thermosensitive liposomal doxorubicin (LTLD, Thermodox), for hepatocellular carcinoma (HCC) lesions 3-7 cm , 2014 .

[23]  S. Feng,et al.  Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation , 2014, Hepatology.

[24]  J. Bruix,et al.  “Very Early” Intrahepatic Cholangiocarcinoma in Cirrhotic Patients: Should Liver Transplantation Be Reconsidered in These Patients? , 2014, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[25]  G. Gores,et al.  Hepatocellular carcinoma: clinical frontiers and perspectives , 2014, Gut.

[26]  Eric W. Klee,et al.  Integrated Genomic Characterization Reveals Novel, Therapeutically Relevant Drug Targets in FGFR and EGFR Pathways in Sporadic Intrahepatic Cholangiocarcinoma , 2014, PLoS genetics.

[27]  J. Llovet,et al.  Liver cancer in 2013: Mutational landscape of HCC—the end of the beginning , 2014, Nature Reviews Clinical Oncology.

[28]  G. Gores,et al.  Pathogenesis, diagnosis, and management of cholangiocarcinoma. , 2013, Gastroenterology.

[29]  Bruno Sangro,et al.  Yttrium 90 radioembolization for the treatment of hepatocellular carcinoma: Biological lessons, current challenges, and clinical perspectives , 2013, Hepatology.

[30]  J. Bruix,et al.  Postprogression survival of patients with advanced hepatocellular carcinoma: Rationale for second‐line trial design , 2013, Hepatology.

[31]  T. Pawlik,et al.  Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas , 2013, Nature Genetics.

[32]  M. Kudo,et al.  Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  L. Jeng,et al.  Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  S. Thongprasert,et al.  Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  M. Kudo,et al.  Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  Jack A. Taylor,et al.  Keratin 19: a key role player in the invasion of human hepatocellular carcinomas , 2013, Gut.

[37]  F. Nicolantonio,et al.  Liquid biopsy: monitoring cancer-genetics in the blood , 2013, Nature Reviews Clinical Oncology.

[38]  G. Gores,et al.  The mTOR pathway in hepatic malignancies , 2013, Hepatology.

[39]  L. Bolondi,et al.  Cost-effectiveness of hepatic resection versus percutaneous radiofrequency ablation for early hepatocellular carcinoma. , 2013, Journal of hepatology.

[40]  S. Imbeaud,et al.  A hepatocellular carcinoma 5-gene score associated with survival of patients after liver resection. , 2013, Gastroenterology.

[41]  Jaw-Town Lin,et al.  Postoperative peg‐interferon plus ribavirin is associated with reduced recurrence of hepatitis C virus‐related hepatocellular carcinoma , 2013, Hepatology.

[42]  Nickolay A. Khazanov,et al.  Identification of targetable FGFR gene fusions in diverse cancers. , 2013, Cancer discovery.

[43]  S. Gabriel,et al.  Prognostic gene expression signature for patients with hepatitis C-related early-stage cirrhosis. , 2013, Gastroenterology.

[44]  S. Hattori,et al.  Clinicopathologic Analysis of Combined Hepatocellular-Cholangiocarcinoma According to the Latest WHO Classification , 2013, The American journal of surgical pathology.

[45]  Shyh-Dar Li,et al.  Hyperthermia-induced drug targeting , 2013, Expert opinion on drug delivery.

[46]  W. Lau,et al.  Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  Wen-Tsung Huang,et al.  Phase III trial of linifanib versus sorafenib in patients with advanced hepatocellular carcinoma (HCC). , 2013 .

[48]  D. Y. Kim,et al.  How to Improve Treatment Outcomes for Hepatocellular Carcinoma of Intermediate and Advanced Stage , 2012, Digestive Diseases.

[49]  F. Roudot-thoraval,et al.  Liver transplantation for hepatocellular carcinoma: a model including α-fetoprotein improves the performance of Milan criteria. , 2012, Gastroenterology.

[50]  Jesse S. Voss,et al.  Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma. , 2012, Human pathology.

[51]  C. Verslype,et al.  Hepatocellular carcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[52]  B. Goh,et al.  Epigenetic therapy using belinostat for patients with unresectable hepatocellular carcinoma: a multicenter phase I/II study with biomarker and pharmacokinetic analysis of tumors from patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research Group. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  M. Kudo.  Treatment of Advanced Hepatocellular Carcinoma with Emphasis on Hepatic Arterial Infusion Chemotherapy and Molecular Targeted Therapy , 2012, Liver Cancer.

[54]  K. Öberg.  Implications for Clinical Practice and Trial Design , 2012 .

[55]  A. Zhu,et al.  Search: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Sorafenib Plus Erlotinib in Patients with Hepatocellular Carcinoma (HCC) , 2012 .

[56]  G. Gores,et al.  Cholangiocarcinomas can originate from hepatocytes in mice. , 2012, The Journal of clinical investigation.

[57]  W. Palmer,et al.  Are common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for intrahepatic cholangiocarcinoma. , 2012, Journal of hepatology.

[58]  J. Bruix,et al.  Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design. , 2012, Journal of hepatology.

[59]  C. Bartolozzi,et al.  Transarterial chemoembolization in very early and early-stage hepatocellular carcinoma patients excluded from curative treatment: a prospective cohort study. , 2012, European journal of radiology.

[60]  E. Alexopoulou,et al.  Chemoembolization With Doxorubicin-Eluting Beads for Unresectable Hepatocellular Carcinoma: Five-Year Survival Analysis , 2012, CardioVascular and Interventional Radiology.

[61]  Beicheng Sun,et al.  Combination of Radiofrequency Ablation with Transarterial Chemoembolization for Hepatocellular Carcinoma: A Meta-Analysis , 2012, Digestive Diseases and Sciences.

[62]  Bin Tean Teh,et al.  Exome sequencing of liver fluke–associated cholangiocarcinoma , 2012, Nature Genetics.

[63]  S. Imbeaud,et al.  Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma , 2012, Nature Genetics.

[64]  V. Mazzaferro,et al.  Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function: SHARP trial subanalyses. , 2012, Journal of hepatology.

[65]  Itzhak Avital,et al.  Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. , 2012, Gastroenterology.

[66]  V. Mazzaferro,et al.  Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib. , 2012, Clinical cancer research : an official journal of the American Association for Cancer Research.

[67]  Bruno Sangro,et al.  Radioembolization for hepatocellular carcinoma. , 2012, Journal of hepatology.

[68]  J. Bruix,et al.  Sorafenib or placebo in combination with transarterial chemoembolization (TACE) with doxorubicin-eluting beads (DEBDOX) for intermediate-stage hepatocellular carcinoma (HCC): Phase II, randomized, double-blind SPACE trial. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[69]  V. Paradis,et al.  Benefit of initial resection of hepatocellular carcinoma followed by transplantation in case of recurrence: An intention‐to‐treat analysis , 2012, Hepatology.

[70]  Jin Wook Chung,et al.  Asian Consensus Workshop Report: Expert Consensus Guideline for the Management of Intermediate and Advanced Hepatocellular Carcinoma in Asia , 2011, Oncology.

[71]  J. Seong,et al.  Radiotherapeutic Strategies in the Management of Hepatocellular Carcinoma , 2011, Oncology.

[72]  Cynthia S. Johnson,et al.  Stereotactic body radiotherapy for primary hepatocellular carcinoma. , 2011, International journal of radiation oncology, biology, physics.

[73]  F. Izzo,et al.  Survival after yttrium‐90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: A European evaluation , 2011, Hepatology.

[74]  M. Kudo,et al.  Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. , 2011, European journal of cancer.

[75]  J. Roberts,et al.  Mixed hepatocellular cholangiocarcinoma and intrahepatic cholangiocarcinoma in patients undergoing transplantation for hepatocellular carcinoma , 2011, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[76]  A. Benson,et al.  Radiographic response to locoregional therapy in hepatocellular carcinoma predicts patient survival times. , 2011, Gastroenterology.

[77]  V. Mazzaferro,et al.  Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization. , 2011, Cancer treatment reviews.

[78]  Arthur Liberzon,et al.  Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma. , 2011, Gastroenterology.

[79]  J. Bruix,et al.  Management of hepatocellular carcinoma: An update , 2011, Hepatology.

[80]  Jian Yu,et al.  Survey of Tyrosine Kinase Signaling Reveals ROS Kinase Fusions in Human Cholangiocarcinoma , 2011, PloS one.

[81]  Jeff Myers,et al.  Interconversion of three measures of performance status: an empirical analysis. , 2010, European journal of cancer.

[82]  P. Majno,et al.  Selection of patients with hepatocellular carcinoma before liver transplantation: need to combine alpha-fetoprotein with morphology? , 2010, Hepatobiliary & pancreatic diseases international : HBPD INT.

[83]  J. Moon,et al.  Combined Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma: Outcome After Liver Transplantation , 2010, Digestive Diseases and Sciences.

[84]  M. Sherman.  The resurrection of alphafetoprotein. , 2010, Journal of hepatology.

[85]  Chien-Jen Chen,et al.  Nomograms for risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[86]  C. Porta,et al.  Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[87]  D. Cunningham,et al.  Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. , 2010, The New England journal of medicine.

[88]  V. Mazzaferro,et al.  Partial hepatectomy versus radiofrequency ablation for hepatocellular carcinoma: Confirming the trial that will never be, and some comments on the indications for liver resection , 2010, Hepatology.

[89]  Derek Y. Chiang,et al.  IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage. , 2010, Journal of hepatology.

[90]  M. Makuuchi,et al.  Overall survival after transarterial lipiodol infusion chemotherapy with or without embolization for unresectable hepatocellular carcinoma: propensity score analysis. , 2010, AJR. American journal of roentgenology.

[91]  T. Roskams,et al.  Pathology of early hepatocellular carcinoma: conventional and molecular diagnosis. , 2010, Seminars in liver disease.

[92]  J. Llovet,et al.  Molecular classification and novel targets in hepatocellular carcinoma: recent advancements. , 2010, Seminars in liver disease.

[93]  T. Vogl,et al.  Prospective Randomized Study of Doxorubicin-Eluting-Bead Embolization in the Treatment of Hepatocellular Carcinoma: Results of the PRECISION V Study , 2009, CardioVascular and Interventional Radiology.

[94]  Derek Y. Chiang,et al.  Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo. , 2009, Journal of hepatology.

[95]  H. Rhim,et al.  Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies , 2009, Hepatology.

[96]  S. Paggi,et al.  Sorafenib in Advanced Hepatocellular Carcinoma , 2008 .

[97]  Derek Y. Chiang,et al.  Pivotal role of mTOR signaling in hepatocellular carcinoma. , 2008, Gastroenterology.

[98]  Kenji Ikeda,et al.  Gene expression in fixed tissues and outcome in hepatocellular carcinoma. , 2008, The New England journal of medicine.

[99]  Derek Y. Chiang,et al.  Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. , 2008, Cancer research.

[100]  J. Trotter,et al.  Total tumor volume predicts risk of recurrence following liver transplantation in patients with hepatocellular carcinoma , 2008, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[101]  C. Bartolozzi,et al.  Doxorubicin-eluting bead-enhanced radiofrequency ablation of hepatocellular carcinoma: a pilot clinical study. , 2008, Journal of hepatology.

[102]  F. Farinati,et al.  Transcatheter Arterial Chemoembolization (TACE) in Hepatocellular Carcinoma (HCC): The Role of Angiogenesis and Invasiveness , 2008, The American Journal of Gastroenterology.

[103]  G. Gores,et al.  EUS-guided FNA of regional lymph nodes in patients with unresectable hilar cholangiocarcinoma. , 2008, Gastrointestinal endoscopy.

[104]  Jin Woo Kim,et al.  EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. , 2008, Cancer research.

[105]  Maria Hawkins,et al.  Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[106]  J. Bruix,et al.  Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma , 2007, Hepatology.

[107]  Luigi Solbiati,et al.  Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: Is resection still the treatment of choice? , 2007, Hepatology.

[108]  J. Bruix,et al.  Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. , 2007, Journal of hepatology.

[109]  S. Boyault,et al.  Differential effects of inactivated Axin1 and activated β-catenin mutations in human hepatocellular carcinomas , 2007, Oncogene.

[110]  S. Boyault,et al.  Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets , 2007, Hepatology.

[111]  S. Thorgeirsson,et al.  Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype. , 2006, The Journal of clinical investigation.

[112]  S. Thorgeirsson,et al.  Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. , 2006, Gastroenterology.

[113]  A. Lloyd,et al.  DC bead: in vitro characterization of a drug-delivery device for transarterial chemoembolization. , 2006, Journal of vascular and interventional radiology : JVIR.

[114]  J. Bruix,et al.  High pathological risk of recurrence after surgical resection for hepatocellular carcinoma: An indication for salvage liver transplantation , 2004, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[115]  Kai Breuhahn,et al.  Molecular Profiling of Human Hepatocellular Carcinoma Defines Mutually Exclusive Interferon Regulation and Insulin-Like Growth Factor II Overexpression , 2004, Cancer Research.

[116]  Michael J Thun,et al.  Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. , 2003, The New England journal of medicine.

[117]  J. Bruix,et al.  Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival , 2003, Hepatology.

[118]  S. Kawasaki,et al.  Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. , 2003, Journal of hepatology.

[119]  Ramon Planas,et al.  Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial , 2002, The Lancet.

[120]  T. Patel,et al.  Worldwide trends in mortality from biliary tract malignancies , 2002, BMC Cancer.

[121]  John Wong,et al.  Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma , 2002, Hepatology.

[122]  A. Venook,et al.  Liver transplantation for hepatocellular carcinoma: Expansion of the tumor size limits does not adversely impact survival , 2001, Hepatology.

[123]  M. Sherman,et al.  Alphafetoprotein: an obituary. , 2001, Journal of hepatology.

[124]  P. Kamath,et al.  A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts , 2000, Hepatology.

[125]  J. Bruix,et al.  Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure. , 1996, Gastroenterology.

[126]  N. Kinukawa,et al.  Risk factors for intrahepatic recurrence in human small hepatocellular carcinoma. , 1995, Gastroenterology.

[127]  S. Hirohashi,et al.  Predictive factors for postoperative recurrence of hepatocellular carcinoma. , 1994, Gastroenterology.

[128]  G. Dusheiko,et al.  Management of hepatocellular carcinoma. , 1992, Journal of hepatology.

[129]  J. Wands,et al.  Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa , 1991, Nature.

[130]  K. Amplatz,et al.  Therapeutic transcatheter arterial embolization. , 1974, Radiology.

[131]  R. Pugh,et al.  Transection of the oesophagus for bleeding oesophageal varices , 1973, The British journal of surgery.

[132]  A. Gasbarrini,et al.  Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. , 2013, The Lancet. Oncology.

[133]  V. Mazzaferro,et al.  EASL-EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma European Association for the Study of the Liver ⇑ , European Organisation for Research and Treatment of Cancer , 2012 .

[134]  Patrick M M Bossuyt,et al.  Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. , 2012, The Lancet. Oncology.

[135]  A. Benson,et al.  Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. , 2010, Gastroenterology.

[136]  L. Mariani,et al.  Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. , 2009, The Lancet. Oncology.

[137]  Yoon-Koo Kang,et al.  Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. , 2009, The Lancet. Oncology.

[138]  ndrea,et al.  Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. , 1996, The New England journal of medicine.

[139]  I. Lax,et al.  Stereotactic high dose fraction radiation therapy of extracranial tumors using an accelerator. Clinical experience of the first thirty-one patients. , 1995, Acta oncologica.

[140]  R. Metcalf,et al.  Mutational hotspot in the p53 gene in human hepatocellular carcinomas. , 1991, Nature.

[141]  A. B. Sukhomlinov,et al.  [Liver cirrhosis]. , 1989, Fel'dsher i akusherka.

[142]  D. Woodfield.  Hepatocellular carcinoma. , 1986, The New Zealand medical journal.